MOR Stock Price, Chart, Stats & News

MorphoSys AG operates as a commercial-stage biopharmaceutical firm, concentrating on the discovery, development, and marketing of therapeutic antibodies. Its primary focus is on addressing cancer and autoimmune conditions, particularly within the United States. The company's lead commercial product is Tafasitamab, an antibody used to treat various B-cell cancers, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.